JUN 10, 2020 7:14 AM PDT

FDA Approves New Antibiotic for Hospital-Acquired Pneumonia

WRITTEN BY: Annie Lennon

The US Food and Drug Administration (FDA) has approved Recarbrio, an antibiotic drug created by pharmaceutical company Merck, to treat different varieties of bacterial pneumonia typically contracted in hospitals. 

Recarbrio is a mixture of antibiotic imipenem-cilastatin and the beta-lactamase inhibitor, relebactam, used to increase the efficiency of the active antibiotic. The drug has previously been approved to treat patients with complicated urinary tract infections and intra-abdominal infections who have limited or no other treatment options. 

Now, the agency has approved the drug for usage against hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by gram-negative microorganisms in people over 18 years old. 

Patients usually contract HABP and VABP types of pneumonia in hospital settings. Symptoms include fever, chills, cough, chest pain, and an increased need for oxygen. 

To assess the safety of the drug for HABP/VABP, researchers conducted a randomized, controlled clinical trial involving 535 with either condition. While 266 patients were treated with Recarbrio intravenously, the remaining 269 were treated with piperacillin-tazobactam, another drug with antibacterial properties. 

In the end, the researchers found that while 21.3% of those on piperacillin-tazobactam died before Day 28 of the study, the same was true for only 15.9% of patients on Recarbrio. Meanwhile, the clinical response at early follow-up was 61% for those on Recarbrio, whereas just 55.8% for the control drug. 

Negative side effects for Recarbrio included anemia, diarrhea, hypokalemia (low potassium levels), and hyponatremia (low sodium levels). Before qualifying for treatment with Recarbrio, patients are urged to share information on previous hypersensitivity reactions to allergens that could hamper treatment. 

The FDA also notes that the drug should not be used in patients prone to seizures and other nervous system disorders. As with almost all antibacterial drugs, Recarbrio leads to Clostridioides difficile-associated diarrhea and may range from mild diarrhea to fatal colitis. 


Sources: FDA, Yahoo News, Drug Topics

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
APR 25, 2022
Health & Medicine
Sex differences in association between cannabis use and diabetes
APR 25, 2022
Sex differences in association between cannabis use and diabetes
A preprint published in Cannabis Cannabinoid Research examined the association between cannabis use and diabetes to dete ...
MAY 15, 2022
Drug Discovery & Development
Implanted Insulin-producing Cells for Diabetes Treatment
MAY 15, 2022
Implanted Insulin-producing Cells for Diabetes Treatment
Type 1 diabetes, which affects about 9 to 10 million people globally, occurs when the immune system incorrectly identifi ...
MAY 25, 2022
Neuroscience
The Connection Between Bizarre Dreams and Deeper Learning
MAY 25, 2022
The Connection Between Bizarre Dreams and Deeper Learning
A study published in eLife found that wakefulness, non-REM, and REM sleep have complementary functions for learning. Uni ...
JUN 04, 2022
Drug Discovery & Development
Antibiotics Reduce Motivation to Exercise in Mice
JUN 04, 2022
Antibiotics Reduce Motivation to Exercise in Mice
Antibiotics may decrease athletes' motivation and endurance via effects on the microbiome. The corresponding study w ...
JUN 19, 2022
Drug Discovery & Development
Oral Immunotherapy for Peanut Allergy Most Effective Before 12 Months Old
JUN 19, 2022
Oral Immunotherapy for Peanut Allergy Most Effective Before 12 Months Old
Oral immunotherapy for peanut allergies is safer and more effective in children under 12 months old than in toddlers and ...
JUN 24, 2022
Drug Discovery & Development
Pain Medications with High Abuse Potential More Likely to Achieve Approval
JUN 24, 2022
Pain Medications with High Abuse Potential More Likely to Achieve Approval
Researchers found that pain medications with a high potential for abuse are more likely to be approved than medications ...
Loading Comments...